RANK-Fc

RANK-Fc is a recombinant fusion protein consisting of the extracellular domain of human receptor activator of nuclear factor-kappa B (RANK) fused to the Fc portion of human IgG. Its mechanism of action is as a **decoy receptor for RANK ligand (RANKL)**, blocking the interaction of RANKL with endogenous RANK and thereby inhibiting the downstream signaling pathways involved in **osteoclast formation, bone resorption, and tumor progression**[2][4][6]. RANK-Fc has demonstrated efficacy in delaying mammary tumor formation in preclinical models and in reducing osteoclast differentiation and bone resorption[2][4][1]. Its pharmacodynamic mechanism is comparable to denosumab and OPG-Fc, acting as a RANKL inhibitor by binding and neutralizing RANKL[2][4][1]. RANK-Fc is used experimentally to investigate the role of RANKL/RANK signaling in diseases such as breast cancer and bone metabolism disorders[2][4][6].

Other names

RANK-Fc fusion protein